ImmuCell (ICCC)
(Delayed Data from NSDQ)
$3.78 USD
+0.01 (0.27%)
Updated Aug 9, 2024 03:16 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ICCC 3.78 +0.01(0.27%)
Will ICCC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ICCC based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ICCC
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024
ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain?
Immucell updates status of product development initiative for Re-Tain
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders